MGAT5 and hepatocellular carcinoma: To determine whether the increased sensitivity of Mgat5-deficient cells to TNF-α– or TRAIL-induced cell death is specific for PDAC or generalizable to other tumor types, we evaluated the effects of Mgat5 KO in 4 non-PDAC cell lines: Lewis lung carcinoma (LLC) cells, MC38 colorectal cancer cells, B16-F10 melanoma cells, and Hep55 HCC cells.